Options for Treating Prediabetes and Diabetes: Get Your Patient to Goal

Celia Levesque MSN, RN, CNS-BC, NP-C, CDE, BC-ADM <u>clevesqu@mdanderson.org</u>

Objectives

- Differentiate types of diabetes and prediabetes
- Describe various treatment options for managing diabetes and prediabetes
- Describe various treatment options for managing diabetes and prediabetes

CDC Diabetes Statistics Report 2017¹

- Diabetes 30.3 million (9.4%)
- Diabetes: 25% in age 65+
- Highest in Asians, non-Hispanic blacks, and Hispanics
- Children: in 2012: 17,900 w T1DM, 5,300 w T2DM
- Prediabetes: 84.1 million (33.9%)
- Prediabetes: 48% in age 65+

Screening for Prediabetes & Diabetes²

- Overweight/obese who have 1+ risk factors
 - $\circ \quad 1^{st}$ degree relative with DM
 - High-risk ethnic group
 - Hx CVD, HTN, HDL < 35, Triglyceride > 250
 - o PCOS
 - o Sedentary lifestyle
 - Other: Acanthosis nigricans
 - o If normal: test at least every 3 years or more often
- GDM lifelong testing every 3 years

Secreted by Adipose Tissue³



| Lept = Leptin | Signals to brain about body fat stores, regulates appetite and energy expenditure |
|------------------------|--|
| Adipo = Adiponectin | Plays role in protection in patho of T2DM and CVD |
| Resi = Resistin | May contribute to insulin resistance |
| TNF = TNF-α | Affects insulin signaling may cause insulin resistance in obesity |
| IL6 = Interleukin-6 | Pro-inflammatory, plays role in lipid and glucose metabolism, and weight |
| | regulation |
| PAI = Plasminogen | Inhibitor of fibrinolytic system by inhibition of activation of plasminogen |
| activator inhibitor 1 | |
| Angi = | Precursor of angiotensin II, regulator of BP and electrolyte homeostasis |
| Angiotensinogen | |
| FFA = Free fatty acids | Oxidized in tissues to produce local energy, substrate for triglyceride and |
| | structural molecular synthesis, involved in development of insulin resistance |
| ASP = acylation | Influences rate of triacylglycerol synthesis in adipose tissue |
| stimulating protein | |
| VEGF = vascular | Stimulates angiogenesis |
| endothelial growth | |
| factor | |
| Adip = Adipsin | Potential relation between complement pathway and adipose tissue metabolism |
| Glyc=Glycerol | Structural component of major classes of biological lipids and gluconeogenic |
| | precursor |
| IGF1= insulin-like | Stimulates proliferation of wide variety of cells and mediates many cells and many |
| growth factor 1 | of the effects of growth hormone |

Diagnosis of Prediabetes/Diabetes²

| | Normal | Prediabetes | Diabetes |
|---------|--------|-------------|--------------|
| Fasting | < 100 | 100-125 | 126 <u>+</u> |
| 2 h PG | <140 | 140-199 | 200 <u>+</u> |
| HbA1c | <5.7 | 5.7-6.4 | 6.5 <u>+</u> |

In absence of unequivocal hyperglycemia, dx requires 2 abnormal tests from 1 or 2 separate test sample(s)

Estimated Average Glucose = AG $_{mg/dL}$ = 28.7 x A1c – 46.7⁴

Causes of Inaccurate HbA1c²

- Hemoglobin variants
- Sickle cell disease
- Pregnancy 2nd or 3rd trimester, Postpartum
- Glucos-6 phosphate dehydrogenase deficiency
- HIV
- Hemodialysis
- Recent blood loss, Blood transfusion
- Erythropoietin therapy



Prediabetes⁵

- Impaired Fasting Glucose
 - Normal insulin sensitivity in skeletal muscle
 - \circ Impaired 1st phase insulin
 - o Decreased liver glucose uptake
 - o Impaired suppression of endogenous glucose production
- Impaired Glucose Tolerance
 - o Severe skeletal muscle insulin resistance
 - o Impaired 2nd phase insulin
 - The 1-hour PP BG is strongest predictor of T2DM
 - If IFG and 1 hr PP > 155 had 4 fold increased risk of T2DM

Treatment of Prediabetes^{2,6}

- Intensive Lifestyle Therapy
 - Weight loss ~7%
 - Nutrition: mostly plant based polyunsaturated/monounsaturaterd fat, avoid trans and saturated fat
 - Exercise: moderate intensity 150 min week + strength training
 - o Moderate alcohol consumption
 - Sleep 7 hours per night
 - No tobacco products
- Dyslipidemia management
- Hypertension management
- Consider Diabetes Medications:



Classifications of Diabetes Mellitus²

- Type 1 DM autoimmune B-cell destruction
- Type 2 DM progressive insulin resistance / B-cell failure
- Gestational DM diagnosed 2nd or 3rd trimester
- Specific types due to other causes
 - Monogenic diabetes syndromes: neonatal, MODY
 - Medications: steroids
 - Cystic fibrosis
 - Pancreatitis

Type 1 Diabetes²

| | Stage 1 | Stage 2 | Stage 3 |
|---------------------|-------------------------|-------------------------|----------------------|
| Characteristics | Autoimmunity | Autoimmunity | Hyperglycemia |
| | Normoglycemia | Normoglycemia | Symptomatic |
| | Presymptomatic | Presymptomatic | |
| Diagnostic Criteria | Multiple autoantibodies | Multiple autoantibodies | Clinical symptoms |
| | No IGT or IFG | Dysglycemia IFG and/or | Diabetes by standard |
| | | IGT | criteria |



Type 1 Diabetes

- Antibodies:
 - o GAD65
 - o Insulin
 - Tyrosine phosphatases IA-2, IA-2B, and ZnT8
- HLA associations
 - o DQA and DQB
- Prone to other autoimmune disorders
 - o Hashimoto thyroiditis
 - o Graves disease
 - o Addison disease
 - o Celiac disease
 - \circ Vitiligo
 - o Autoimmune hepatitis
 - o Myasthenia gravis
 - o Pernicious anemia



Treatment of Diabetes²

- Uses person-centered and strength-based language
 - o Active listening
 - o Elicit patient preferences and beliefs
 - o Assesses literacy, numeracy, barriers
- Multidisciplinary team

Patient Centered Approach

- Assess key patient characteristics
- Consider factors that impact care
- Shared decision making
- Agree on management plan
- Implement management plan
- Ongoing monitoring / adjust plan as needed

Initial Diabetes Evaluation

- DM hx including hx of DM education
- Family hx
- Hx of DM complications and medical
- Lifestyle assessment
- Current medication/vaccines
- Psychosocial assessment

Physical exam

- Ht, wt, BMI, growth & development in children
- BP, orthostatic BP if indicated
- Fundoscopic exam by eye specialist
- Thyroid palpation
- Skin exam (acanthosis, injection sites)
- Foot exam

Lab evaluation

- A1c
- Lipid profile
- Liver function
- Spot urinary albumin-to-creatinine ratio
- Serum creatinine and eGFR
- TSH if autoimmune T1DM
- Vitamin B12 if on metformin
- Serum K+ if on ACEI, ARB, or diuretics

Chronic Kidney Disease Stages

| Stage | eGFR |
|----------------------|-------------|
| No clinical evidence | <u>≥</u> 60 |
| 1 | > 90 |
| 2 | 60-89 |
| 3 | 30-59 |
| 4 | 15-29 |
| 5 | <15 |

Refer to nephrologist if uncertain about etiology, difficulty in managing complications of CKD including anemia, secondary hyperparathyroidism, metabolic bone disease, resistant hypertension, electrolyte disturbances, eGFR < 30

Diabetic Retinopathy

- Initial exam
 - Type 1 after 5 years duration
 - Type 2 at time of dx
- Retinal photography with remote reading by an ophthalmologist or optometrist can be screening tool until comprehensive eye exam can be done
- Pregnant or planning pregnancy: eye exsm before or in 1st trimester
- Optimize blood glucose, blood pressure, and lipids

Treatment of Diabetic Retinopathy

- If any DR, refer to a specialist experienced with management of DR
- Treatment
 - Laser photocoagulation
 - \circ Intravitreous injections of antivascular endothelial growth factor ranibizumab
 - o Intravitreous injections of antivascular endothelial growth factor

Goal setting

- A1c / Blood glucose / BP / lipid goals
- Self management goals

A1c / Blood Glucose Goals

| | Less Stringent | More stringent |
|-------------------|----------------|----------------|
| Hypoglycemia risk | High risk | Low risk |
| Disease duration | Long duration | Short duration |
| Life expectancy | Short | Long |

| Comorbidities | Severe | None |
|--------------------|-------------------|-------------------|
| Vascular disease | Severe | None |
| Patient preference | Wants less burden | Highly motivated |
| Resources/support | Limited | Readily available |

ADA General Recommendations for A1c, Glucose, BP and Lipids

| Health status | Rationale | A1c goal | FBS/ac | Bedtime BG | BP | Lipids |
|----------------|----------------|----------|---------|------------|---------|------------|
| Healthy, few | Long life | <7.5% | 90-130 | 90-150 | <140/90 | Statin if |
| complications, | | | | | | possible |
| good | | | | | | |
| cognition | | | | | | |
| Intermed, | Less life exp, | <8% | 90-150 | 100-180 | <140/90 | Statin if |
| multiple | high hypo | | | | | possible |
| complications, | risk | | | | | |
| impaired | | | | | | |
| cognition | | | | | | |
| Very complex | Benefit of | <8.5% | 100-180 | 110-200 | <150/90 | Consider |
| limited life, | tight control | | | | | benefit of |
| severe | uncertain | | | | | statin? |
| cognitive | | | | | | |
| impairment | | | | | | |

Nutrition

- No such thing as a "diabetic diet"
- No recommendations for macronutrients
- Mostly plant based, healthy fats, high fiber, low sugar
- Limit alcohol, sodium, sugar sweetened beverages
- Individualized meal planning with registered dietitian
- Promote healthy eating pattern to achieve weight, BP, lipid goals

Dyslipidemia Management

- Intensive lifestyle
- Assess ASCVD Risk: American College of Cardiology/American Heart Association ASCVD risk calculator
- <u>http://tools.acc.org/ASCVD-Risk-Estimator-Plus</u>
- Does not account for duration of diabetes or presence of diabetes complications
- Risk factors: DM, HTN, Fam Hx, low HDL-C, smoking, CKD 3-4

| | HIGH RISK | VERY HIGH RISK | EXTREME RISK |
|-----------|-----------------------|-----------------------|----------------|
| | DM but no other major | DM + major ASCVD risk | DM plus dx CVD |
| | risk and/or age <40 | | |
| | Desirable | Desirable | Desirable |
| LDL-C | <100 | <70 | <55 |
| Non HDL-C | <130 | <100 | <80 |
| TG | <150 | <150 | <150 |
| Аро В | <90 | <80 | <70 |

Lipid Management

| No statin | Moderate statin | High statin | |
|--|----------------------------------|----------------------------------|--|
| Pregnancy | < age 40 with ASCVD risk factors | All ages with ASCVD or 10 yr CVD | |
| | | risk > 20% | |
| < 40 no ASCVD risk fx | Age >40 without ASCVD | Consider in those with multiple | |
| | | ASCVD risk fx | |
| If don't tolerate statin dose, try alternate statin, decrease dose or frequency | | | |
| If not at goal with statin: Intensify statin, add ezetimibe, PCSK9i, colesevelam or niacin | | | |
| If triglycerides over 500: add fibrate, Rx-grade omega-3 fatty acids, niacin | | | |

Statin Therapy

| High intensity statin ♥☑≥ 50% | Moderate intensity ♥☑≥ 30-50% |
|-------------------------------|-------------------------------|
| Atorvastatin 40-80 mg | Atorvastatin 10-20 mg |
| Rosuvastatin 20-40 mg | Rosuvastatin 5-10 mg |
| | Simvastatin 20-40 mg |
| | Pravastatin 40-80 mg |
| | Lovastatin 40 mg |
| | Fluvastatin XL 80 mg |
| | Pitavastatin 2-4 mg |

Blood Pressure

- Measure at each visit
- Measured by a trained professional
- Seated position, feet on floor, arm supported at level of the heart after 5 minutes of rest
- Cuff size appropriate
- Elevated values confirmed on another day

Blood Pressure Goals

- If DM + HTN and ASCVD or 10-year risk > 15% may choose target of <130/80 if can safely do so
- Lower risk individuals < 140/90

HTN TX: Initial BP < 160/100

- Start with 1 agent + intensive lifestyle
- No albuminuria: ACEI or ARB or β -blocker or CCB or thiazide diuretic
- Albuminuria: ACEI or ARB
- Not meeting target: add different drug class from ACEI/ARB, β-blocker, CCB, thiazide diuretic (don't combine ACEI and ARB).
- If not meeting goal with above agents consider adding mineralocorticoid receptor antagonist, α-blocker, central agents, vasodilator, aldosterone antagonist or refer to specialist

HTN TX: Initial BP < 160/100

- No albuminuria: Start with 2 agents: ACEI/ARB or β-blocker, or CCB, or thiazide diuretic
- Albuminuria: ACEI or ARB **AND** β-blocker, or CCB or thiazide diuretic
- Not meeting target: add different drug class from ACEI/ARB, β-blocker, CCB, thiazide diuretic (don't combine ACEI and ARB).
- If not meeting goal with above agents consider adding mineralocorticoid receptor antagonist, α-blocker, central agents, vasodilator, or aldosterone antagonist or refer to specialist

References

- 1. Centers for Disease Control and Prevention. National diabetes statistics report 2017. *Atlanta, GA: Centers for Disease Control and Prevention.* 2017.
- 2. American Diabetes Association. Standards of Medical Care in Diabetes 2019. *Diabetes Care.* 2019;42:S81.
- 3. Coelho M, Oliveira T, Fernandes R. State of the art paper Biochemistry of adipose tissue: an endocrine organ. *Archives of Medical Science.* 2013;9(2):191-200.
- 4. Nathan DM, Kuenen J, Borg R, et al. Translating the A1C assay into estimated average glucose values. *Diabetes Care.* 2008;31(8):1473-1478.
- 5. Alatrach M, Agyin C, Adams J, DeFronzo RA, Abdul-Ghani MA. Decreased basal hepatic glucose uptake in impaired fasting glucose. *Diabetologia*. 2017;60(7):1325-1332.
- 6. Garber AJ, Abrahamson MJ, Barzilay JI, et al. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM– 2018 EXECUTIVE SUMMARY. *AACE Clinical Case Reports.* 2018.